clinical trial · NCT00662740
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic ObstructiveFDC tiotropium / salmeterolPlaceboSalmeterolTiotropium (Spiriva®)
brief summary
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.
started
Apr 15, 2008
primary completion
Nov 21, 2008
completion
Nov 21, 2008
last updated
Oct 29, 2026
official title
1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol